Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
171 hedge funds and large institutions have $540M invested in Eagle Pharmaceuticals, Inc. in 2020 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 66 increasing their positions, 54 reducing their positions, and 18 closing their positions.
8,306% more call options, than puts
Call options by funds: $1.34M | Put options by funds: $16K
44% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 18
22% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 54
4% more funds holding
Funds holding: 164 → 171 (+7)
15% less capital invested
Capital invested by funds: $633M → $540M (-$92.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$17.1M |
| 2 |
BlackRock
New York
|
+$7.8M |
| 3 |
BIP
Brandes Investment Partners
La Jolla,
California
|
+$6.47M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$5.6M |
| 5 |
Morgan Stanley
New York
|
+$5.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$21.2M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$17.2M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$8.46M |
| 4 |
LSV Asset Management
Chicago,
Illinois
|
-$6.77M |
| 5 |
WG
Winton Group
London,
United Kingdom
|
-$3.86M |
EGRX Hedge Fund Activity: Q3 2020 in Review
171 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q3 2020, worth a combined $540M — down 15% from $633M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new EGRX positions and 18 closed out — a net gain of 8 holders — while 66 added to existing stakes and 54 trimmed.
The largest buyer was Armistice Capital, adding an estimated $17.1M. The largest seller was Park West Asset Management, cutting an estimated $21.2M.
- 171 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q3 2020, up from 164 in Q2 2020.
- Funds reported $540M of Eagle Pharmaceuticals, Inc. stock for Q3 2020, down 15% quarter-over-quarter.
- 26 funds opened new Eagle Pharmaceuticals, Inc. positions in Q3 2020 and 18 closed out, a net change of +8 holders.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q3 2020 was Armistice Capital, an estimated $17.1M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q3 2020 was Park West Asset Management, an estimated $21.2M sold.
Based on aggregated 13F filings for Q3 2020.